DXVX Strikes a Landmark 300 Billion Won Deal for mRNA Cancer Vaccine with U.S. Biotech Firm

DXVX, a Korean biotech firm, signs a 300 billion won deal with a U.S. company for an mRNA cancer vaccine, showcasing promising anti-cancer effects and a significant revenue-sharing...